CoRegen is pioneering a novel approach to cancer treatment by targeting the SRC-3 gene in Regulatory T (Treg) cells, a type of adoptive cell therapy (ACT), enabling the immune system to recognize and eliminate solid tumors. Research from the O'Malley Lab at Baylor College of Medicine has shown in preclinical models that genetically modifying Tregs alters their behavior, allowing them to penetrate tumors, release cytokines, and recruit immune cells to eradicate tumors.
